New hope for hard-to-treat stomach infections: rifabutin combo tested

NCT ID NCT05874544

Completed Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 34 times

Summary

This study tested whether a rifabutin-based triple therapy can effectively treat Helicobacter pylori infections that did not respond to previous treatments. 360 adults with confirmed H. pylori and prior treatment experience were randomly assigned to one of three rescue therapies. The main goal was to see how well each therapy eradicated the bacteria, measured by a breath test six weeks after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200127, China
Shanghai Songjiang District Central Hospital

Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital of Zhejiang University school of Medicine

Hangzhou, Zhejiang, China

Conditions

Explore the condition pages connected to this study.

HELICOBACTER PYLORI INFECTION